These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 21211590

  • 21. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers.
    Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, Levartovsky D, Litinsky I, Kaufman I, Wigler I, Mendelson E, Elkayam O.
    Ann Rheum Dis; 2006 Feb; 65(2):191-4. PubMed ID: 16014674
    [Abstract] [Full Text] [Related]

  • 22. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P.
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [Abstract] [Full Text] [Related]

  • 23. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination.
    Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, Rimmelzwaan GF, Kroon FP.
    Ann Rheum Dis; 2008 May; 67(5):713-6. PubMed ID: 17965123
    [Abstract] [Full Text] [Related]

  • 24. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity.
    Salemi S, Picchianti-Diamanti A, Germano V, Donatelli I, Di Martino A, Facchini M, Nisini R, Biselli R, Ferlito C, Podestà E, Cappella A, Milanetti F, Rossi F, Amodeo R, Tabacco F, Di Rosa R, Laganà B, D Amelio R.
    Clin Immunol; 2010 Feb; 134(2):113-20. PubMed ID: 19846344
    [Abstract] [Full Text] [Related]

  • 25. Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports.
    Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ.
    Scand J Immunol; 2011 Aug; 74(2):210-8. PubMed ID: 21438900
    [Abstract] [Full Text] [Related]

  • 26. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma.
    Brydak LB, Machała M, Centkowski P, Warzocha K, Biliński P.
    Vaccine; 2006 Nov 10; 24(44-46):6620-3. PubMed ID: 16870313
    [Abstract] [Full Text] [Related]

  • 27. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab.
    Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM.
    Ann Rheum Dis; 2007 Oct 10; 66(10):1402-3. PubMed ID: 17881666
    [No Abstract] [Full Text] [Related]

  • 28. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
    Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loët X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X.
    Arthritis Rheum; 2013 Sep 10; 65(9):2253-61. PubMed ID: 23740460
    [Abstract] [Full Text] [Related]

  • 29. Rituximab-treated patients have a poor response to influenza vaccination.
    Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ET, Sullivan KE.
    J Clin Immunol; 2013 Feb 10; 33(2):388-96. PubMed ID: 23064976
    [Abstract] [Full Text] [Related]

  • 30. Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients.
    Avetisyan G, Ragnavölgyi E, Toth GT, Hassan M, Ljungman P.
    Bone Marrow Transplant; 2005 Sep 10; 36(5):411-5. PubMed ID: 15980884
    [Abstract] [Full Text] [Related]

  • 31. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity.
    Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, Cardelli P, Rossi F, D'Amelio R.
    Vaccine; 2006 Apr 12; 24(16):3217-23. PubMed ID: 16466833
    [Abstract] [Full Text] [Related]

  • 32. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.
    Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM, IMAGE Investigators.
    Ann Rheum Dis; 2011 Jan 12; 70(1):39-46. PubMed ID: 20937671
    [Abstract] [Full Text] [Related]

  • 33. Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis.
    Kogure T, Harada N, Tatsumi T, Fujinaga H.
    Clin Rheumatol; 2014 Mar 12; 33(3):323-8. PubMed ID: 24445384
    [Abstract] [Full Text] [Related]

  • 34. Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients.
    Vogtländer NP, Brown A, Valentijn RM, Rimmelzwaan GF, Osterhaus AD.
    Vaccine; 2004 Jun 02; 22(17-18):2199-201. PubMed ID: 15149777
    [Abstract] [Full Text] [Related]

  • 35. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W, Buczek J, Bednarek A, Lewandowicz J, Kucharz E.
    Pol Merkur Lekarski; 2010 Dec 02; 29(174):365-8. PubMed ID: 21298986
    [Abstract] [Full Text] [Related]

  • 36. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.
    Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, Choi Y, Winthrop KL, Lee EB.
    Ann Rheum Dis; 2018 Jun 02; 77(6):898-904. PubMed ID: 29572291
    [Abstract] [Full Text] [Related]

  • 37. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency.
    van Assen S, de Haan A, Holvast A, Horst G, Gorter L, Westra J, Kallenberg CG, Telgt DS, Palache AM, Giezeman KM, Bijl M.
    Clin Immunol; 2011 Nov 02; 141(2):161-8. PubMed ID: 21889412
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
    Crowe BA, Brühl P, Gerencer M, Schwendinger MG, Pilz A, Kistner O, Koelling-Schlebusch K, Aichinger G, Singer J, Zeitlinger M, Müller M, Ehrlich H, Barrett PN.
    Vaccine; 2010 Dec 16; 29(2):166-73. PubMed ID: 21055500
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T.
    N Engl J Med; 2004 Jun 17; 350(25):2572-81. PubMed ID: 15201414
    [Abstract] [Full Text] [Related]

  • 40. Keeping the memory of influenza viruses.
    Combadière B, Sibéril S, Duffy D.
    Pathol Biol (Paris); 2010 Apr 17; 58(2):e79-86. PubMed ID: 20303671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.